Elevated norepinephrine may be an etiological factor in a wide range of diseases: Age-related macular degeneration, systemic lupus erythematosus, atrial fibrillation, metabolic syndrome

Medical Hypotheses

Volumn 80, Issue 5, 2013, Pages 558-563

  Fitzgerald, Paul J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; NORADRENALIN;

ARTICLE; BIPOLAR DISORDER; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETICS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOTHESIS; MENTAL STRESS; METABOLIC SYNDROME X; OBESITY; RETINA MACULA DEGENERATION; SIGNAL TRANSDUCTION; STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ATRIAL FIBRILLATION; EVIDENCE-BASED MEDICINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACULAR DEGENERATION; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NOREPINEPHRINE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84875602372     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.01.018     Document Type: Article

References (81)

1. Batsis J.A., Nieto-Martinez R.E., Lopez-Jimenez F. Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007, 82:509-524.
2. Morton N.M., Densmore V., Wamil M., et al. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action. Diabetes 2005, 54:3371-3378.
3. Fitzgerald P.J. Is norepinephrine an etiological factor in some types of cancer?. Int J Cancer 2009, 124:257-263.
4. Deng C., Kaplan M.J., Yang J., et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.
5. Jimerson D.C., Nurnberger J.I., Post R.M., Gershon E.S., Kopin I.J. Plasma MHPG in rapid cyclers and healthy twins. Arch Gen Psychiatry 1981, 38:1287-1290.
6. Solt V.B., Brown M.R., Kennedy B., Kolterman O.G., Ziegler M.G. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens 1990, 3:823-828.
7. Masuo K., Katsuya T., Fu Y., Rakugi H., Ogihara T., Tuck M.L. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5years. Circulation 2005, 111:3429-3434.
8. van Leeuwen R., Tomany S.C., Wang J.J., et al. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from three continents. Ophthalmology 2004, 111:1169-1175.
9. Suvarna B.S. Secrets of omega-3 oil. Kathmandu Univ Med J 2008, 6:406-411.
10. Bourre J.M. Dietary omega-3 fatty acids for women. Biomed Pharmacother 2007, 61:105-112.
11. Duan Y., Mo J., Klein R., et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007, 114:732-737.
12. Tan J.S., Mitchell P., Smith W., Wang J.J. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007, 114:1143-1150.
13. Fraser-Bell S., Wu J., Klein R., et al. Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 2008, 145:308-316.
14. Krishnaiah S., Das T.P., Kovai V., Rao G.N. Associated factors for age-related maculopathy in the adult population in southern India: the Andhra Pradesh Eye Disease Study. Br J Ophthalmol 2009, 93:1146-1150.
15. Hyman L., Schachat A.P., He Q., Leske M.C. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-related macular degeneration risk factors study group. Arch Ophthalmol 2000, 118:351-358.
16. Smith W., Mitchell P., Leeder S.R., Wang J.J. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998, 116:583-587.
17. Schaumberg D.A., Christen W.G., Hankinson S.E., Glynn R.J. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol 2001, 119:1259-1265.
18. Moeini H.A., Masoudpour H., Ghanbari H. A study of the relation between body mass index and the incidence of age related macular degeneration. Br J Ophthalmol 2005, 89:964-966.
19. Capellino S., Lowin T., Angele P., Falk W., Grifka J., Straub R.H. Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2008, 35:91-99.
20. Sandler B., Aronson P. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 1993, 41:343-345.
21. Witman G., Davis R. A lupus erythematosus syndrome induced by clonidine hydrochloride. R I Med J 1981, 64:147-150.
22. Hutchinson G.A., Nehall J.E., Simeon D.T. Psychiatric disorders in systemic lupus erythematosus. West Indian Med J 1996, 45:48-50.
23. Brey R.L., Holliday S.L., Saklad A.R., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214-1220.
24. Bachen E.A., Chesney M.A., Criswell L.A. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009, 61:822-829.
25. Gamez-Nava J.I., Gonzalez-Lopez L., Ramos-Remus C., Fonseca-Gomez M.M., Cardona-Munoz E.G., Suarez-Almazor M.E. Autonomic dysfunction in patients with systemic lupus erythematosus. J Rheumatol 1998, 25:1092-1096.
26. McLaurin E.Y., Holliday S.L., Williams P., Brey R.L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005, 64:297-303.
27. Molina M.J., Mayor A.M., Franco A.E., Morell C.A., Lopez M.A., Vila L.M. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. J Clin Rheumatol 2007, 13:202-204.
28. Oeser A., Chung C.P., Asanuma Y., Avalos I., Stein C.M. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005, 52:3651-3659.
29. Zonana-Nacach A., Santana-Sahagun E., Jimenez-Balderas F.J., Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008, 14:74-77.
30. Adams S.G., Dammers P.M., Saia T.L., Brantley P.J., Gaydos G.R. Stress, depression, and anxiety predict average symptom severity and daily symptom fluctuation in systemic lupus erythematosus. J Behav Med 1994, 17:459-477.
31. Hinrichsen H., Folsch U., Kirch W. Modulation of the immune response to stress in patients with systemic lupus erythematosus: review of recent studies. Eur J Clin Invest 1992, 22(Suppl 1):21-25.
32. Pawlak C.R., Jacobs R., Mikeska E., et al. Patients with systemic lupus erythematosus differ from healthy controls in their immunological response to acute psychological stress. Brain Behav Immun 1999, 13:287-302.
33. Jacobs R., Pawlak C.R., Mikeska E., et al. Systemic lupus erythematosus and rheumatoid arthritis patients differ from healthy controls in their cytokine pattern after stress exposure. Rheumatology (Oxford) 2001, 40:868-875.
34. Ward M.M., Marx A.S., Barry N.N. Psychological distress and changes in the activity of systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41:184-188.
35. Workman A.J. Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:235-249.
36. Anderson J.L., Prystowsky E.N. Sotalol: an important new antiarrhythmic. Am Heart J 1999, 137:388-409.
37. Parvez B., Chopra N., Rowan S., et al. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 2012, 59:49-56.
38. Simpson C.S., Ghali W.A., Sanfilippo A.J., Moritz S., Abdollah H. Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. Am Heart J 2001, 142:E3.
39. Stewart F.M., Singh Y., Persson S., Gamble G.D., Braatvedt G.D. Atrial fibrillation: prevalence and management in an acute general medical unit. Aust N Z J Med 1999, 29:51-58.
40. Healey J.S., Wharton S., Al-Kaabi S., et al. Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. Can J Cardiol 2006, 22:485-488.
41. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2-9.
42. Jongnarangsin K., Chugh A., Good E., et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2008, 19:668-672.
43. Tedrow U.B., Conen D., Ridker P.M., et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 2010, 55:2319-2327.
44. Badheka A.O., Rathod A., Kizilbash M.A., et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010, 123:646-651.
45. Wilhelmsen L., Rosengren A., Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med 2001, 250:382-389.
46. Eaker E.D., Sullivan L.M., Kelly-Hayes M., D'Agostino R.B., Benjamin E.J. Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med 2005, 67:692-696.
47. Kalman J.M., Munawar M., Howes L.G., et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg 1995, 60:1709-1715.
48. Gould P.A., Esler M.D., Kaye D.M. Chronic atrial fibrillation does not influence the magnitude of sympathetic overactivity in patients with heart failure. Eur Heart J 2003, 24:1657-1662.
49. Gould P.A., Yii M., McLean C., et al. Evidence for increased atrial sympathetic innervation in persistent human atrial fibrillation. Pacing Clin Electrophysiol 2006, 29:821-829.
50. Mancia G., Bousquet P., Elghozi J.L., et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007, 25:909-920.
51. Rupp H., Jacob R. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target?. Med Hypotheses 1995, 44:217-225.
52. Grassi G., Quarti-Trevano F., Seravalle G., Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 2007, 17:473-481.
53. van Reedt Dortland A.K., Giltay E.J., van Veen T., Zitman F.G., Penninx B.W. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 2010, 122:30-39.
54. Dell'Omo G., Penno G., Pucci L., et al. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis 2005, 16:67-73.
55. Carella A.M., Antonucci G., Conte M., Di Pumpo M., Giancola A., Antonucci E. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 2010, 6:215-221.
56. Jacob S., Rett K., Wicklmayr M., Agrawal B., Augustin H.J., Dietze G.J. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996, 14:489-494.
57. Taylor V., MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034-1041.
58. Cardenas J., Frye M.A., Marusak S.L., et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008, 106:91-97.
59. Garcia-Portilla M.P., Saiz P.A., Benabarre A., et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008, 106:197-201.
60. Puustinen P.J., Koponen H., Kautiainen H., Mantyselka P., Vanhala M. Psychological distress predicts the development of the metabolic syndrome: a prospective population-based study. Psychosom Med 2011, 73:158-165.
61. Jakovljevic M., Saric M., Nad S., Topic R., Vuksan-Cusa B. Metabolic syndrome, somatic and psychiatric comorbidity in war veterans with post-traumatic stress disorder: preliminary findings. Psychiatr Danub 2006, 18:169-176.
62. Bove M., Carnevali L., Cicero A.F., et al. Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. Aging Ment Health 2010, 14:801-806.
63. Brunner E.J., Hemingway H., Walker B.R., et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002, 106:2659-2665.
64. Lee Z.S., Critchley J.A., Tomlinson B., et al. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 2001, 50:135-143.
65. Grassi G., Dell'Oro R., Quarti-Trevano F., et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005, 48:1359-1365.
66. Telles R., Lanna C., Ferreira G., Ribeiro A. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010, 19:803-809.
67. Mok C.C., Poon W.L., Lai J.P., et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 2010, 39:42-49.
68. Nitsch D., Douglas I., Smeeth L., Fletcher A. Age-related macular degeneration and complement activation-related diseases: a population-based case-control study. Ophthalmology 2008, 115:1904-1910.
69. Seferovic P.M., Ristic A.D., Maksimovic R., et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford) 2006, 45(Suppl. 4):39-42.
70. Chamberlain A.M., Agarwal S.K., Ambrose M., Folsom A.R., Soliman E.Z., Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010, 159:850-856.
71. van der Goes M.C., Bossema E.R., Hartkamp A., et al. Cortisol during the day in patients with systemic lupus erythematosus or primary Sjogren's syndrome. J Rheumatol 2011, 38:285-288.
72. Harle P., Straub R.H., Wiest R., et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis 2006, 65:51-56.
73. Fitzgerald P.J. Is elevated noradrenaline an aetiological factor in a number of diseases?. Auton Autacoid Pharmacol 2009, 29:143-156.
74. Fitzgerald P.J. Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2010, 2:1-3.
75. Fitzgerald P.J. Beta blockers, norepinephrine, and cancer: an epidemiological view point. Clin Epidemiol 2012, 4:151-156.
76. Fitzgerald P.J. Is elevated norepinephrine an etiological factor in some cases of epilepsy?. Seizure 2010, 19:311-318.
77. Fitzgerald P.J. Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease?. Curr Alzheimer Res 2010, 7:506-516.
78. Kaarniranta K., Salminen A., Haapasalo A., Soininen H., Hiltunen M. Age-related macular degeneration (AMD): alzheimer's disease in the eye?. J Alzheimer's Dis 2011, 24:615-631.
79. Choi J.K., Lym Y.L., Moon J.W., Shin H.J., Cho B. Diabetes mellitus and early age-related macular degeneration. Arch Ophthalmol 2011, 129:196-199.
80. Gonzalez-Duarte A., Cantu-Brito C.G., Ruano-Calderon L., Garcia-Ramos G. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008, 59:320-323.
81. Lin H.C., Chien C.W., Hu C.C., Ho J.D. Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. Ophthalmology 2010, 117:2088-2095.